<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01183403</url>
  </required_header>
  <id_info>
    <org_study_id>GETAID 2008-3</org_study_id>
    <nct_id>NCT01183403</nct_id>
  </id_info>
  <brief_title>CE-U and MRE to Predict the Efficacy of Anti-TNF Therapy in Crohn's Disease</brief_title>
  <acronym>CREOLE</acronym>
  <official_title>Value of Contrast-enhanced Ultrasonography and Magnetic Resonance Enterography to Predict the Efficacy of Anti-TNF Therapy in Crohn's Disease Complicated by Symptomatic Small Bowel Stricture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The value of anti-TNF therapy in intestinal strictures related to Crohn's disease (CD) has
      not been clearly demonstrated. The results reported by some teams suggest no beneficial
      effect or even an increased risk of bowel obstruction in the case of stricture, while other
      publications indicate a favourable action of anti-TNF in this setting. The efficacy of
      anti-TNF in patients with intestinal stricture related to Crohn's disease could depend on the
      lesions responsible for the stricture, as anti-TNF agents are probably effective in
      inflammatory forms and useless or even potentially harmful in fibrotic forms. In practice,
      the decision is currently empirical and a trial of anti-TNF therapy is often proposed.

      In view of the high incidence of intestinal strictures in CD and the need for a treatment as
      effective as anti-TNF in this setting, it is important to more clearly define the indications
      of these treatments guided by the information provided by modern imaging.

      The aim of this prospective study is to determine whether certain signs detected by MR
      enterography and contrast-enhanced ultrasonography can help to predict failure of anti-TNF
      therapy in patients with CD presenting a symptomatic stricture of the small bowel and
      scheduled to receive this treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>% of failure defined by the development of at least one of events (obstructive symptoms, activity of the disease..)</measure>
    <time_frame>6 months minus baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of the obstructive symptom scale at the various visits between D0 and W24</measure>
    <time_frame>6 months minus baseline</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">80</enrollment>
  <condition>Crohn's Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients with ileal Crohn's disease complicated by symptomatic stricture after failure of
        corticosteroids and/or immunosuppressives
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Crohn's disease defined according to the usual endoscopic, histological, and
             radiological criteria

          -  Small bowel (jejunum or ileum) stricture identified by radiography or endoscopy

          -  Obstructive symptoms greater than or equal to 3 on a scale from 0 to 6 evaluated over
             the last 8 weeks

          -  Failure of corticosteroids and/or immunosuppressives and indication for anti-TNF
             therapy

        Exclusion Criteria:

          -  Nonresolving complete bowel obstruction

          -  Previous anti-TNF therapy

          -  Contraindication to anti-TNF therapy:

               -  Intra-abdominal, intra-mural or extramural abscess

               -  Active infection

               -  Severe infection during the previous 2 months

               -  Nontreated latent tuberculosis

               -  Heart failure

               -  Active malignancy during the previous 5 years

               -  Demyelinating neurological disease

          -  Modification of the treatment of Crohn's disease during the previous two months:
             azathioprine, mercaptopurine, methotrexate, thalidomide

          -  Contraindication to MR enterography or contrast-enhanced ultrasonography
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoram BOUHNIK, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franck CARBONNEL, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ulb - Clinique Saint Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Besancon</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Avicennes</name>
      <address>
        <city>Bobigny</city>
        <zip>93200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bicetre</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chru Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU NICE</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Lariboisiere</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital St Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Reims</name>
      <address>
        <city>Reims</city>
        <zip>51000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.getaid.org</url>
  </link>
  <reference>
    <citation>Bernstein CN, Greenberg H, Boult I, Chubey S, Leblanc C, Ryner L. A prospective comparison study of MRI versus small bowel follow-through in recurrent Crohn's disease. Am J Gastroenterol. 2005 Nov;100(11):2493-502.</citation>
    <PMID>16279905</PMID>
  </reference>
  <reference>
    <citation>Biancone L, Calabrese E, Petruzziello C, Onali S, Caruso A, Palmieri G, Sica GS, Pallone F. Wireless capsule endoscopy and small intestine contrast ultrasonography in recurrence of Crohn's disease. Inflamm Bowel Dis. 2007 Oct;13(10):1256-65.</citation>
    <PMID>17577246</PMID>
  </reference>
  <reference>
    <citation>Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med. 2007 Nov 29;357(22):2277-84. Review.</citation>
    <PMID>18046031</PMID>
  </reference>
  <reference>
    <citation>Chiorean MV, Sandrasegaran K, Saxena R, Maglinte DD, Nakeeb A, Johnson CS. Correlation of CT enteroclysis with surgical pathology in Crohn's disease. Am J Gastroenterol. 2007 Nov;102(11):2541-50. Epub 2007 Sep 26.</citation>
    <PMID>17900329</PMID>
  </reference>
  <reference>
    <citation>Esteban JM, Aleixandre A, Hurtado MJ, Maldonado L, Mora FJ, Nogués E. Contrast-enhanced power Doppler ultrasound in the diagnosis and follow-up of inflammatory abdominal masses in Crohn's disease. Eur J Gastroenterol Hepatol. 2003 Mar;15(3):253-9.</citation>
    <PMID>12610320</PMID>
  </reference>
  <reference>
    <citation>Giorgio A, Ferraioli G, Tarantino L, de Stefano G, Scala V, Scarano F, Coppola C, Del Viscovo L. Contrast-enhanced sonographic appearance of hepatocellular carcinoma in patients with cirrhosis: comparison with contrast-enhanced helical CT appearance. AJR Am J Roentgenol. 2004 Nov;183(5):1319-26.</citation>
    <PMID>15505297</PMID>
  </reference>
  <reference>
    <citation>Guidi L, De Franco A, De Vitis I, Armuzzi A, Semeraro S, Roberto I, Papa A, Bock E, Gasbarrini G, Fedeli G. Contrast-enhanced ultrasonography with SonoVue after infliximab therapy in Crohn's disease. Eur Rev Med Pharmacol Sci. 2006 Jan-Feb;10(1):23-6.</citation>
    <PMID>16494107</PMID>
  </reference>
  <reference>
    <citation>Holtmann M, Wanitschke R, Helisch A, Bartenstein P, Galle PR, Neurath M. [Anti-TNF antibodies in the treatment of inflammatory intestinal stenoses in Crohn's disease]. Z Gastroenterol. 2003 Jan;41(1):11-7. German.</citation>
    <PMID>12541166</PMID>
  </reference>
  <reference>
    <citation>Louis E, Boverie J, Dewit O, Baert F, De Vos M, D'Haens G; Belgian IBD Research Group. Treatment of small bowel subocclusive Crohn's disease with infliximab: an open pilot study. Acta Gastroenterol Belg. 2007 Jan-Mar;70(1):15-9.</citation>
    <PMID>17619533</PMID>
  </reference>
  <reference>
    <citation>Masselli G, Brizi GM, Parrella A, Minordi LM, Vecchioli A, Marano P. Crohn disease: magnetic resonance enteroclysis. Abdom Imaging. 2004 May-Jun;29(3):326-34.</citation>
    <PMID>15354341</PMID>
  </reference>
  <reference>
    <citation>Masselli G, Casciani E, Polettini E, Gualdi G. Comparison of MR enteroclysis with MR enterography and conventional enteroclysis in patients with Crohn's disease. Eur Radiol. 2008 Mar;18(3):438-47. Epub 2007 Sep 25.</citation>
    <PMID>17899102</PMID>
  </reference>
  <reference>
    <citation>Negaard A, Mulahasanovic A, Reisaeter LA, Aasekjaer K, Sandvik L, Klow NE. Crohn's disease evaluated with magnetic resonance enteroclysis: diagnostic performance of experienced and inexperienced readers before and after training. Acta Radiol. 2008 Nov;49(9):967-74. doi: 10.1080/02841850802409539.</citation>
    <PMID>18925449</PMID>
  </reference>
  <reference>
    <citation>Negaard A, Sandvik L, Mulahasanovic A, Berstad AE, Klöw NE. Magnetic resonance enteroclysis in the diagnosis of small-intestinal Crohn's disease: diagnostic accuracy and inter- and intra-observer agreement. Acta Radiol. 2006 Dec;47(10):1008-16.</citation>
    <PMID>17135001</PMID>
  </reference>
  <reference>
    <citation>Parente F, Greco S, Molteni M, Anderloni A, Maconi G, Bianchi Porro G. Modern imaging of Crohn's disease using bowel ultrasound. Inflamm Bowel Dis. 2004 Jul;10(4):452-61. Review.</citation>
    <PMID>15475759</PMID>
  </reference>
  <reference>
    <citation>De Pascale A, Garofalo G, Perna M, Priola S, Fava C. Contrast-enhanced ultrasonography in Crohn's disease. Radiol Med. 2006 Jun;111(4):539-50. Epub 2006 May 25. English, Italian.</citation>
    <PMID>16779540</PMID>
  </reference>
  <reference>
    <citation>Pelletier AL, Kalisazan B, Wienckiewicz J, Bouarioua N, Soulé JC. Infliximab treatment for symptomatic Crohn's disease strictures. Aliment Pharmacol Ther. 2009 Feb 1;29(3):279-85. doi: 10.1111/j.1365-2036.2008.03887.x. Epub 2008 Nov 8.</citation>
    <PMID>19035967</PMID>
  </reference>
  <reference>
    <citation>Di Sabatino A, Fulle I, Ciccocioppo R, Ricevuti L, Tinozzi FP, Tinozzi S, Campani R, Corazza GR. Doppler enhancement after intravenous levovist injection in Crohn's disease. Inflamm Bowel Dis. 2002 Jul;8(4):251-7.</citation>
    <PMID>12131608</PMID>
  </reference>
  <reference>
    <citation>Rieder F, Brenmoehl J, Leeb S, Schölmerich J, Rogler G. Wound healing and fibrosis in intestinal disease. Gut. 2007 Jan;56(1):130-9. Review.</citation>
    <PMID>17172588</PMID>
  </reference>
  <reference>
    <citation>Di Sabatino A, Pender SL, Jackson CL, Prothero JD, Gordon JN, Picariello L, Rovedatti L, Docena G, Monteleone G, Rampton DS, Tonelli F, Corazza GR, MacDonald TT. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology. 2007 Jul;133(1):137-49. Epub 2007 May 5.</citation>
    <PMID>17631138</PMID>
  </reference>
  <reference>
    <citation>Sallomi DF. The use of contrast-enhanced power Doppler ultrasound in the diagnosis and follow-up of inflammatory abdominal masses associated with Crohn's disease. Eur J Gastroenterol Hepatol. 2003 Mar;15(3):249-51. Review.</citation>
    <PMID>12610319</PMID>
  </reference>
  <reference>
    <citation>Schlottmann K, Kratzer W, Schölmerich J. Doppler ultrasound and intravenous contrast agents in gastrointestinal tract disorders: current role and future implications. Eur J Gastroenterol Hepatol. 2005 Mar;17(3):263-75. Review.</citation>
    <PMID>15716649</PMID>
  </reference>
  <reference>
    <citation>Schreyer AG, Geissler A, Albrich H, Schölmerich J, Feuerbach S, Rogler G, Völk M, Herfarth H. Abdominal MRI after enteroclysis or with oral contrast in patients with suspected or proven Crohn's disease. Clin Gastroenterol Hepatol. 2004 Jun;2(6):491-7.</citation>
    <PMID>15181618</PMID>
  </reference>
  <reference>
    <citation>Serra C, Menozzi G, Labate AM, Giangregorio F, Gionchetti P, Beltrami M, Robotti D, Fornari F, Cammarota T. Ultrasound assessment of vascularization of the thickened terminal ileum wall in Crohn's disease patients using a low-mechanical index real-time scanning technique with a second generation ultrasound contrast agent. Eur J Radiol. 2007 Apr;62(1):114-21. Epub 2007 Jan 18.</citation>
    <PMID>17239555</PMID>
  </reference>
  <reference>
    <citation>Solt J, Hertelendi A, Szilágyi K. [Balloon catheter dilatation of lower gastrointestinal tract stenoses: long-term results]. Orv Hetil. 2002 Aug 4;143(31):1835-40. Hungarian.</citation>
    <PMID>12187577</PMID>
  </reference>
  <reference>
    <citation>Sorrentino D. Role of biologics and other therapies in stricturing Crohn's disease: what have we learnt so far? Digestion. 2008;77(1):38-47. doi: 10.1159/000117306. Epub 2008 Feb 19. Review.</citation>
    <PMID>18285676</PMID>
  </reference>
  <reference>
    <citation>Warnaar N, Hofker HS, Maathuis MH, Niesing J, Bruggink AH, Dijkstra G, Ploeg RJ, Schuurs TA. Matrix metalloproteinases as profibrotic factors in terminal ileum in Crohn's disease. Inflamm Bowel Dis. 2006 Sep;12(9):863-9.</citation>
    <PMID>16954805</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2009</study_first_submitted>
  <study_first_submitted_qc>August 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2010</study_first_posted>
  <last_update_submitted>June 21, 2015</last_update_submitted>
  <last_update_submitted_qc>June 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stricture</keyword>
  <keyword>anti-TNF</keyword>
  <keyword>ileal Crohn'Disease</keyword>
  <keyword>patients with ileal Crohn's disease complicated by</keyword>
  <keyword>symptomatic stricture after failure of corticosteroids</keyword>
  <keyword>and/or immunosuppressives</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

